Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
New FDA Warning: Hearing Impairment Risks in TEPEZZA
The US Food and Drug Administration (FDA) has taken action to update the warning label on Horizon Pharmaceutical’s TEPEZZA, a drug used to treat thyroid eye disease (TED), to include the risk of hearing impairment or loss. The recent addition…
Edenlux’s Otus Personal EYE-Trainer | OBN
The Otus personal eye-trainer, developed by Edenlux, has launched a campaign through Indiegogo. The device uses training called Vision Therapy to relieve the stress of the eyes. Vision Therapy is an exercise that repeats the contraction and relaxation of the…
FDA Approves Vuity for Twice-Daily Dosing in Presbyopia
AbbVie, the parent company of Allergan, has announced that the FDA has granted approval for the use of Vuity (pilocarpine HCl ophthalmic solution) 1.25% twice a day in adults suffering from presbyopia. The second dose, consisting of an additional drop…
FDA Accepts Application for Genentech’s Vabysmo for RVO
Genentech announced that the FDA has accepted the company’s supplemental biologics license application (sBLA) for Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The sBLA is based on data from the phase 3 BALATON and…
Norlase Raises $11M in Funding for ECHO Pattern Laser
Norlase, a leading laser technology company, has recently secured its largest investment round to date, raising $11 million. This significant funding will empower Norlase to expedite the production ramp-up of its cutting-edge ECHO pattern laser, which recently received FDA clearance…
Stuart Therapeutics and Glaukos’ Exclusive License Deal
Stuart Therapeutics announced that it has signed an exclusive agreement with Glaukos Corporation. In this agreement, Glaukos gains exclusive global rights to develop and market Stuart’s proprietary drug candidate, ST-113, which focuses on neuroprotection in the context of glaucoma. ST-113,…
Alimera Wraps Synchronicity Study Enrollment for Yutiq in Uveitis
Alimera Sciences has reached its enrollment target for the Synchronicity study, marking a significant milestone in the prospective, open-label clinical investigation of Yutiq (fluocinolone acetonide intravitreal implant 0.18mg). The study focuses on assessing the safety and efficacy of Yutiq in…
VSY Biotechnology Attends the 35th APACRS Congress
VSY Biotechnology participated in the 35th APACRS Congress held at the Suntec Singapore Convention & Exhibition Centre in Singapore from June 8-10, 2023. The company showcased its latest product, the AcrivaUD Trinova Pro C Pupil Adaptive® with Sinusoidal Vision Technology…
Harrow Secures US and Canadian Rights to Vevye
Harrow has recently announced a significant development by entering the prescription dry eye disease treatment market. The company has successfully struck a deal to acquire the commercial rights for Vevye (cyclosporine ophthalmic solution 0.1%) in both the United States and…
2023 Recap: Top 15 Firsts in Ophthalmology
In a year marked by groundbreaking achievements, the field of ophthalmology witnessed a series of historic firsts, pushing the boundaries of innovation and patient care. Here are the noteworthy milestones: Pioneering the integration of technology into glaucoma management, the world’s…